Doubling Of Capacity

Advanced Medical Solutions Grp PLC
27 July 2001


For Immediate Release:                              27 July 2001

                         ADVANCED MEDICAL SOLUTIONS
 ANNOUNCES DOUBLING OF CAPACITY IN BIOPOLYMER FIBRE PRODUCTION & EXPANSION OF
                               RESEARCH EFFORT

Winsford, Cheshire, UK: Advanced Medical Solutions Group plc ('AMS' or 'the
Company'), a recognised global producer of advanced materials for woundcare
applications, announces a £315,000 investment in upgrading key production
processes, effectively doubling its capacity to produce biopolymer fibres,
such as alginate - one of AMS' key product areas.

Alginate is produced from seaweed and is used in woundcare due to its
haemostatic qualities and its ability to absorb large amounts of exudate
(discharge). As announced earlier this year one of AMS's key customers,
Johnson & Johnson Consumer Products, uses alginate supplied by AMS for a
proprietary product for the USA first aid market.

The Company will partially fund this project with a recently received SMART
Award that will provide up to £105,000. The SMART Award Scheme allows
companies to reclaim up to one third of the cost of an approved development
project. Sir John Harvey-Jones presented AMS's Award, at the recent SMART
awards ceremony at the Manufacturing Institute at Trafford Park, Manchester.

AMS intends to channel part of the SMART funds to its research division to
help finance the development of its new material and device technologies.

Chief Executive Officer of AMS, Don Evans, commented:

'Our alginate business goes from strength to strength and the upgrading of
these facilities will allow us to meet increasing demand from our global
partners in both Professional and Consumer Woundcare.

'I am delighted that we have received the SMART Award  It not only recognises
the high standards that the Company maintains, but will also help us to move
our Winsford based manufacturing operation to another level.  The funds will
also aid us in developing skills in-house to enable the production of fibrous
scaffolds from natural biopolymers.  These scaffolds will then be fabricated
into medical devices for tissue engineering - a key focus for the Company as
it moves into higher value product markets.'


                                   - ENDS -



For further information, please contact:

Advanced Medical Solutions Group plc          Tel: [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                       Tel: [phone]
Nicola How / Fergus Mellon

Notes to Editors:
www.admedsol.com

Founded in 1991 and floated on the Full List of the London Stock Exchange in
1996, Advanced Medical Solutions is focused on the design, development and
manufacture of innovative and technologically advanced products for woundcare
and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast and Smith + Nephew / Beiersdorf.

In addition to the Professional and Consumer Woundcare divisions, AMS has
established a Research & Technology Division.  This was set up in 1999 to ring
fence technical expertise to develop technology platforms for the future. The
key focus of Research & Technology is to develop new material and device
technologies for commercialisation.